Oesophageal sensation in response to high PCO 2 and acidic solutions in nonerosive reflux disease

European Journal of Clinical Investigation

Volumn 42, Issue 2, 2012, Pages 195-202

  Hershcovici, Tiberiu ^a   Poh, Choo H ^a   Fass, Ofer Z ^a   Ashpole, Nicole ^a   Akiba, Yasutada ^b   Guillén Rodríguez, Jose M ^c   Kaunitz, Jonathan D ^b   Fass, Ronnie ^a  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acid perfusion; Heartburn; High PCO 2 solution; Nonerosive reflux disease

Indexed keywords

CARBON DIOXIDE; HYDROCHLORIC ACID;

ACID TOLERANCE; ADULT; AGED; ARTICLE; CARBON DIOXIDE TENSION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; ESOPHAGUS FUNCTION; FEMALE; HEARTBURN; HUMAN; MALE; NON EROSIVE REFLUX DISEASE; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; PROPRIOCEPTION; PROSPECTIVE STUDY; SENSATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARBON DIOXIDE; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; ESOPHAGEAL PH MONITORING; ESOPHAGUS; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROCHLORIC ACID; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SENSORY THRESHOLDS; YOUNG ADULT;

EID: 84855492236     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02560.x     Document Type: Article

References (43)

1. Fass R, Naliboff B, Higa L, Johnson C, Kodner A, Munakata J et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998;115:1363-73.
2. Miwa H, Minoo T, Hojo M, Yaginuma R, Nagahara A, Kawabe M et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. Aliment Pharmacol Ther 2004;20(Suppl 1):112-7.
3. Nagahara A, Miwa H, Minoo T, Hojo M, Kawabe M, Osada T et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol 2006;40:891-5.
4. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001;96:303-14.
5. Brown CM, Rees WD. Review article: factors protecting the oesophagus against acid-mediated injury. Aliment Pharmacol Ther 1995;9:251-62.
6. Sarosiek J, Yu Z, Namiot Z, Rourk RM, Hetzel DP, McCallum RW. Impact of acid and pepsin on human esophageal prostaglandins. Am J Gastroenterol 1994;89:588-94.
7. Sarosiek J, McCallum RW. Mechanisms of oesophageal mucosal defence. Baillieres Best Pract Res Clin Gastroenterol 2000;14:701-17.
8. Stolte M, Vieth M, Schmitz JM, Alexandridis T, Seifert E. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus. Scand J Gastroenterol 2000;35:1125-30.
9. Tanaka S, Chu S, Hirokawa M, Montrose MH, Kaunitz JD. Direct measurement of acid permeation into rat oesophagus. Gut 2003;52:775-83.
10. Akiba Y, Mizumori M, Kuo M, Ham M, Guth PH, Engel E et al. CO2 chemosensing in rat oesophagus. Gut 2008;57:1654-64.
11. Gasiorowska A, Navarro-Rodriguez T, Wendel C, Krupinski E, Perry ZH, Koenig K et al. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009;104:2005-13.
12. Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994;69:539-47.
13. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160-4.
14. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993;306:1437-40.
15. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252-8.
16. Geers C, Gros G. Carbon dioxide transport and carbonic anhydrase in blood and muscle. Physiol Rev 2000;80:681-715.
17. Gracely RH, McGrath F, Dubner R. Ratio scales of sensory and affective verbal pain descriptors. Pain 1978;5:5-18.
18. Christie KN, Thomson C. The distribution of carbonic anhydrase II in human, pig and rat oesophageal epithelium. Histochem J 2000;32:753-7.
19. Christie KN, Thomson C, Morley S, Anderson J, Hopwood D. Carbonic anhydrase is present in human oesophageal epithelium and submucosal glands. Histochem J 1995;27:587-90.
20. Christie KN, Thomson C, Xue L, Lucocq JM, Hopwood D. Carbonic anhydrase isoenzymes I, II, III, and IV are present in human esophageal epithelium. J Histochem Cytochem 1997;45:35-40.
21. Parkkila S, Parkkila AK, Juvonen T, Rajaniemi H. Distribution of the carbonic anhydrase isoenzymes I, II, and VI in the human alimentary tract. Gut 1994;35:646-50.
22. Guarino MP, Cheng L, Ma J, Harnett K, Biancani P, Altomare A et al. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol Motil 2010;22:746-51, e219.
23. Shieh KR, Yi CH, Liu TT, Tseng HL, Ho HC, Hsieh HT et al. Evidence for neurotrophic factors associating with TRPV1 gene expression in the inflamed human esophagus. Neurogastroenterol Motil 2010;22:971-7, e252.
24. Elder JB, Hearn AR. Intragastric PCO2 in man and calculated gastric bicarbonate concentrations: effect of carbenoxolone sodium. Scand J Gastroenterol Suppl 1980;65:19-27.
25. Stevens MH, Thirlby RC, Feldman M. Mechanism for high PCO2 in gastric juice: roles of bicarbonate secretion and CO2 diffusion. Am J Physiol 1987;253(4 Pt 1):G527-30.
26. Brown CM, Snowdon CF, Slee B, Sandle LN, Rees WD. Measurement of bicarbonate output from the intact human oesophagus. Gut 1993;34:872-80.
27. Mertz-Nielsen A, Hillingso J, Bukhave K, Rask-Madsen J. Reappraisal of bicarbonate secretion by the human oesophagus. Gut 1997;40:582-6.
28. Hirano I. Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease - Bilitec, intraluminal impedance and Bravo capsule pH monitoring. Aliment Pharmacol Ther 2006;23(Suppl 1):12-24.
29. Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF, Timmer R, Smout AJ. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor? Am J Gastroenterol 2008;103:2446-53.
30. Iwakiri K, Sano H, Tanaka Y, Kawami N, Umezawa M, Futagami S et al. Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy. Digestion 2010;82:156-61.
31. Fass R. Proton pump inhibitor failure - what are the therapeutic options? Am J Gastroenterol 2009;104(Suppl 2):S33-8.
32. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55:1398-402.
33. Zerbib F, Roman S, Ropert A, des Varannes SB, Pouderoux P, Chaput U et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;101:1956-63.
34. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008;57:156-60.
35. Bautista JM, Wong WM, Pulliam G, Esquivel RF, Fass R. The value of ambulatory 24hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005;50:1909-15.
36. Bredenoord AJ, Weusten BL, Curvers WL, Timmer R, Smout AJ. Determinants of perception of heartburn and regurgitation. Gut 2006;55:313-8.
37. Dubin A, Badie J, Fernandez S, Estenssoro E, Canales H, Bordoli G et al. Lack of agreement between tonometric and gastric juice partial carbon dioxide tension. Crit Care 2000;4:249-54.
38. Guzman JA, Lacoma FJ, Kruse JA. Gastric and esophageal intramucosal PCO2 (PiCO2) during endotoxemia: assessment of raw PiCO2 and PCO2 gradients as indicators of hypoperfusion in a canine model of septic shock. Chest 1998;113:1078-83.
39. Sato Y, Weil MH, Tang W. Tissue hypercarbic acidosis as a marker of acute circulatory failure (shock). Chest 1998;114:263-74.
40. Rukwied R, Chizh BA, Lorenz U, Obreja O, Margarit S, Schley M et al. Potentiation of nociceptive responses to low pH injections in humans by prostaglandin E2. J Pain 2007;8:443-51.
41. Akiba Y, Kaunitz JD. Lafutidine, a protective H receptor antagonist, enhances mucosal defense in rat esophagus. Dig Dis Sci 2010;55:3063-9.
42. Lasch H, Castell DO, Castell JA. Evidence for diminished visceral pain with aging: studies using graded intraesophageal balloon distension. Am J Physiol 1997;272(1 Pt 1):G1-3.
43. van Malenstein H, Farre R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2008;103:1021-8.